Snapshot from Jun 26, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Reproxalap
Other

Reproxalap

Tracked across 1 events · 80 articles · First seen Apr 24, 2026 · Last active Jun 09, 2026

Sentiment
-80
Attention
6
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
Events (1)
6 -80
Business
Aldeyra Therapeutics Faces Class Actions
Multiple investor-rights law firms, including Bronstein, Gewirtz & Grossman, LLC, The Schall Law Firm, Rosen Law Firm, and Pomerantz LLP, have filed or are reminding investors about class action lawsuits against Aldeyra Therapeutics. These lawsuits…
Impact: Reproxalap is an investigational drug candidate by Aldeyra Therapeutics for dry eye disease, which failed to receive United States — Food and Drug Administration approval, leading to the company's stock decline and the class action lawsuit.
Apr 24, 2026 · 80 articles
NEWSDESK
Track Reproxalap live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.